New Member Spotlight: Cymbathera
We warmly welcome Cymbathera as a new member of our life science park, located in The Spark!
There will be an opportunity to meet Cymbathera's co-founder, Göran Brorsson, on 14 April, when he hosts a Science for Breakfast at Medicon Village.
Cymbathera is a bioelectronic product company, built on decades of neuroimmunology research by scientists at Feinstein Institute for Medical Research Northwell Health and the Karolinska Institutet. Their founders created Cymbathera because chronic pain and inflammation affect millions of people – and current solutions often rely on long-term medication with adverse effects, or incomplete relief. Modern science has proven that the body already has a powerful, drug-free regulating system: the vagus nerve system. Cymbathera focuses on translating this science into a non-invasive medical device currently under clinical and regulatory evaluation. By targeting vagus nerve signaling, they aim to support the body’s natural ability to regulate inflammation and pain and without systemic side effects. Their purpose is to translate clinically proven neuroscience into accessible, safe bioelectronic solutions to help as many people as possible move toward a life with less pain, less inflammation, and more balance.
We asked co-founder Göran Brorsson three key questions to highlight what makes Cymbathera a trusted and versatile life science partner:
How can the life science community benefit from your membership at Medicon Village?
Cymbathera operates at the intersection of neuroscience and immunology, exploring how the nervous system may influence inflammatory processes through bioelectronic approaches. Being part of Medicon Village gives us the opportunity to contribute to a highly collaborative environment where research, clinical insight, and innovation come together.
Our foundation is built on decades of scientific work by our founders, Professor Ulf Andersson and Dr. Kevin J. Tracey, who have been instrumental in advancing the understanding of the inflammatory reflex. At the same time, we are supported by a strong executive team, led by CEO Göran Brorsson, who brings extensive experience from the MedTech industry and scaling growth-oriented companies.
We see Medicon Village as a platform for meaningful knowledge exchange, not only within academia and clinical research, but also across emerging business models. As a MedTech company increasingly exploring direct-to-consumer approaches, we are particularly interested in sharing insights with other D2C and health-focused companies working at the intersection of science, technology, and user experience.
What makes Cymbathera stand out compared to your competition?
Cymbathera stands out through its unique combination of scientific depth, technological focus, and long-term vision.
Our co-founder Kevin J. Tracey, MD, Feinstein Institute in New York, is widely recognized for discovering the inflammatory reflex and helping define the field of bioelectronic medicine. Together with co-founder Professor Ulf Andersson, Karolinska Institutet, a leading researcher in inflammation, this foundation gives Cymbathera a strong scientific credibility that few companies in the field can match.
We’re not just building devices; we’re building a deeper understanding of how the body regulates itself. By combining science, targeting, and intuitive design, we aim to develop bioelectronic solutions that are both advanced and accessible.
Where is chronic inflammatory disease treatment headed and how does Cymbathera fit in?
Chronic pain and inflammation-related diseases affect millions globally, yet treatment remains insufficient. Many patients depend on long-term medication, often resulting in systemic side effects or incomplete relief. This highlights the need for innovative approaches that bridge scientific insight and clinical relevance.
Over recent decades, research has revealed a powerful built-in regulatory system mediated via the vagus nerve. Through the inflammatory reflex, the vagus nerve system directly counteracts dysregulated inflammation. This has opened up an entirely new field – bioelectronic medicine – focused on modulating these neuronal pathways.
Growing clinical evidence now supports this approach. Studies from The Feinstein Institutes for Medical Research have demonstrated that vagus nerve stimulation can restore the function of the inflammatory reflex and reduce inflammation in conditions such as rheumatoid arthritis, even in patients refractory to conventional therapy.
At Cymbathera, we are building on this scientific and clinical foundation by translating these insights into a non-invasive medical device, now under clinical and regulatory evaluation. By targeting vagus nerve signaling, we aim to support the body’s natural ability to regulate inflammation and pain – without systemic exposure.
We see strong potential across several chronic inflammatory conditions, including rheumatoid arthritis, inflammatory bowel disease, and other disorders rooted in immune dysregulation. Our ambition is to help shift treatment from broad systemic interventions toward targeted, mechanism-based approaches.
Ultimately, our purpose is to translate clinically established neuroscience into safe, accessible bioelectronic solutions, with the goal of helping more people live with less pain, reduced inflammatory burden, and improved quality of life.
For more information on how Cymbathera can support your next project, visit https://www.cymbathera.com.